.png){kind=icon}
返回
Pyrotinib: First Global Approval
.png){kind=icon}
PRE
AI
DOI：10.1007/s40265-018-0997-0.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. Based on positive results in a phase II trial, the drug recently received conditional approval in China for use in combination with capecitabine for the treatment of HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy. This article summarizes the milestones in the development of pyrotinib leading to this first global approval for the treatment of HER2-positive advanced breast cancer.
Keyword:
TYROSINE KINASE INHIBITOR
SAFETY
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
引用论文
HER2-positive breast cancer: Current and new therapeutic strategiesHER2-positive乳腺癌: 当前和新的治疗策略.png)
BREAST
BREASTIF7.9
PREAI
分享收藏Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication
OAAI
OAAI分享收藏Autonomous exploration for radioactive sources localization based on radiation field reconstructionOAAI
OAAI分享收藏Treatment of advanced HER2-positive breast cancer: 2018 and beyond晚期HER2-positive乳腺癌的治疗: 2018及以后CANCER TREATMENT REVIEWS
CANCER TREATMENT REVIEWSIF10.5
PREAI
分享收藏 没有更多内容
没有更多内容